Literature DB >> 16253815

Preparation of high specific activity (86)Y using a small biomedical cyclotron.

Jeongsoo Yoo1, Lucie Tang, Todd A Perkins, Douglas J Rowland, Richard Laforest, Jason S Lewis, Michael J Welch.   

Abstract

86Y is an attractive PET radionuclide due to its intermediate half-life. (86)Y was produced via the 86Sr(p,n)86Y nuclear reaction. Enriched SrCO3 or SrO was irradiated with 2-6 microA of beam current for <4 h on a CS-15 cyclotron. It was shown that the SrO target could withstand at least 6 microA of beam current, a significant improvement over a maximum of 2 microA on the SrCO3 target. Average yields of 4.5 mCi/microA.h were achieved with SrO, which represent 71% of the theoretical yield, compared to 2.3 mCi/microA.h with SrCO3. The radioisotopic contaminants were (86m)Y (220%), 87Y (0.27%), (87m)Y (0.43%) and 88Y (0.024%). 86Y was isolated in an electrochemical cell consisting of three Pt electrodes. The solution was electrolyzed at 2000 mA (40 min) using two Pt plate electrodes. A second electrolysis (230 mA for 20 min) was performed using one Pt plate and a Pt wire. On average, 97.1% of the 86Y was recollected on the Pt wire after a second electrolysis. The (86)Y was collected from the Pt wire using 2.8 M HNO3/EtOH (3:1). After evaporation, 86Y was reconstituted in 100 microl of 0.1 M HCl. Target materials were recovered as SrCO3 and then converted to SrO by thermal decomposition at 1150 degrees C. Specific activity of 86Y was determined to be 29+/-19 mCi/microg via titration of 86Y(OAc)3 with DOTA or DTPA. We have established techniques for the routine, economical production of high purity, high specific activity 86Y on a small biomedical cyclotron that are translatable to other institutions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253815     DOI: 10.1016/j.nucmedbio.2005.06.007

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  23 in total

1.  Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Authors:  Sangeeta Ray Banerjee; Catherine A Foss; Mrudula Pullambhatla; Yuchuan Wang; Senthamizhchelvan Srinivasan; Robert F Hobbs; Kwamena E Baidoo; Martin W Brechbiel; Sridhar Nimmagadda; Ronnie C Mease; George Sgouros; Martin G Pomper
Journal:  J Nucl Med       Date:  2015-02-26       Impact factor: 10.057

4.  Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.

Authors:  Lihui Wei; Xiuli Zhang; Fabio Gallazzi; Yubin Miao; Xiaofang Jin; Martin W Brechbiel; Heng Xu; Thomas Clifford; Michael J Welch; Jason S Lewis; Thomas P Quinn
Journal:  Nucl Med Biol       Date:  2009-03-26       Impact factor: 2.408

5.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

6.  Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Authors:  Sibaprasad Bhattacharyya; Manish Dixit
Journal:  Dalton Trans       Date:  2011-05-03       Impact factor: 4.390

7.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

Review 8.  Production of radiometals in liquid targets.

Authors:  Sergio J C do Carmo; Peter J H Scott; Francisco Alves
Journal:  EJNMMI Radiopharm Chem       Date:  2020-01-10

9.  Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.

Authors:  Nilantha Bandara; Tamila J Stott Reynolds; Rebecca Schehr; Rajendra P Bandari; Philipp J Diebolder; Stephanie Krieger; Jingli Xu; Yubin Miao; Buck E Rogers; Charles J Smith
Journal:  Nucl Med Biol       Date:  2018-06-08       Impact factor: 2.408

10.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.